

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 12 Match STN Content and Features to Your Information
Needs, Quickly and Conveniently
NEWS 3 JAN 25 Annual Reload of MEDLINE database
NEWS 4 FEB 16 STN Express Maintenance Release, Version 8.4.2, Is
Now Available for Download
NEWS 5 FEB 16 Derwent World Patents Index (DWPI) Revises Indexing
of Author Abstracts
NEWS 6 FEB 16 New FASTA Display Formats Added to USGENE and PCTGEN
NEWS 7 FEB 16 INPADOCDB and INPAFAMDB Enriched with New Content
and Features
NEWS 8 FEB 16 INSPEC Adding Its Own IPC codes and Author's E-mail
Addresses
NEWS 9 APR 02 CAS Registry Number Crossover Limits Increased to
500,000 in Key STN Databases
NEWS 10 APR 02 PATDPAFULL: Application and priority number formats
enhanced
NEWS 11 APR 02 DWPI: New display format ALLSTR available
NEWS 12 APR 02 New Thesaurus Added to Derwent Databases for Smooth
Sailing through U.S. Patent Codes
NEWS 13 APR 02 EMBASE Adds Unique Records from MEDLINE, Expanding
Coverage back to 1948
NEWS 14 APR 07 CA/CAplus CLASS Display Streamlined with Removal of
Pre-IPC 8 Data Fields
NEWS 15 APR 07 50,000 World Traditional Medicine (WTM) Patents Now
Available in CAplus
NEWS 16 APR 07 MEDLINE Coverage Is Extended Back to 1947
NEWS 17 JUN 16 WPI First View (File WPIFV) will no longer be
available after July 30, 2010
NEWS 18 JUN 18 DWPI: New coverage - French Granted Patents
NEWS 19 JUN 18 CAS and FIZ Karlsruhe announce plans for a new
STN platform
NEWS 20 JUN 18 IPC codes have been added to the INSPEC backfile
(1969-2009)
NEWS 21 JUN 21 Removal of Pre-IPC 8 data fields streamline displays
in CA/CAplus, CASREACT, and MARPAT
NEWS 22 JUN 21 Access an additional 1.8 million records exclusively
enhanced with 1.9 million CAS Registry Numbers --
EMBASE Classic on STN
NEWS 23 JUN 28 Introducing "CAS Chemistry Research Report": 40 Years
of Biofuel Research Reveal China Now Atop U.S. in
Patenting and Commercialization of Bioethanol
NEWS 24 JUN 29 Enhanced Batch Search Options in DGENE, USGENE,
and PCTGEN

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,

AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus *

FILE 'HOME' ENTERED AT 10:42:54 ON 08 JUL 2010

FILE 'REGISTRY' ENTERED AT 10:43:06 ON 08 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 JUL 2010 HIGHEST RN 1229513-84-1
DICTIONARY FILE UPDATES: 7 JUL 2010 HIGHEST RN 1229513-84-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stn/gen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10590845.str



chain nodes :

10 17

ring nodes :

1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 18 19 20 21 22 23

chain bonds :

9-10 10-11 17-18

ring bonds :

1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16 18-19 18-23 19-20 20-21 21-22 22-23

exact/norm bonds :

1-7 2-9 7-8 8-9 9-10 17-18 18-19 18-23 19-20 20-21 21-22 22-23

exact bonds :

10-11

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

```
=> s 11
SAMPLE SEARCH INITIATED 10:43:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 974 TO ITERATE

100.0% PROCESSED      974 ITERATIONS          5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:   17608 TO    21352
PROJECTED ANSWERS:       5 TO     234

L2      5 SEA SSS SAM L1

=> s 11 full
FULL SEARCH INITIATED 10:43:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 19206 TO ITERATE

100.0% PROCESSED      19206 ITERATIONS         90 ANSWERS
SEARCH TIME: 00.00.01

L3      90 SEA SSS FUL L1


=> s 13 and caplus/lc
    71340420 CAPPLUS/LC
L4      87 L3 AND CAPPLUS/LC

=> s 13 not 14
L5      3 L3 NOT L4

=> d 15 1-3
```

L5 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2010 ACS on STN
RN 864172-47-4 REGISTRY
ED Entered STN: 29 Sep 2005
CN 4-Morpholineethanamine, N-[(*cis*-4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)cyclohexyl)methyl]- (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H42 N6 O
CI COM
SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L5 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2010 ACS on STN
RN 864171-77-7 REGISTRY
ED Entered STN: 29 Sep 2005
CN 1-Pyrrolidineethanamine, N-[(*trans*-4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino)cyclohexyl)methyl]- (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H44 N6
CI COM
SR CA

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2010 ACS on STN
RN 864171-59-5 REGISTRY
ED Entered STN: 29 Sep 2005
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (CA INDEX NAME)
MF C29 H36 N6
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> fil caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	203.34	203.56

FILE 'CAPLUS' ENTERED AT 10:43:53 ON 08 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 8 Jul 2010 VOL 153 ISS 2
FILE LAST UPDATED: 7 Jul 2010 (20100707/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2010

CAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007281164 CAPLUS
 DOCUMENT NUMBER: 146:309333
 TITLE: Preventives and/or remedies for X-ray induced lung injury containing GPR4 signaling inhibitors
 INVENTOR(S): Hiura, Naoko; Mie, Genya; Oshima, Etsuo; Manabe, Haruhiko; Watanabe, Akihiko
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 43pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:
 PATENT NO. KIND DATE APPLICATION NO. DATE
 JP 2007063261 A 20070315 JP 2006-207645 20060731
 PRIORITY APPLN. INFO.: JP 2005-223037 A 20050801


OTHER SOURCE(S): MARPAT 146:309333
 AB The invention provides a preventive and/or remedy for X-ray induced lung injury characterized by containing a component which inhibits signal transduction of GPR4 (G protein-coupled receptor 4), including an antisense oligonucleotide, antibody, and imidazopyridine derivative For example, a compound 2-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-ylmethyl)-8-(4-methylpiperazin-1-ylmethyl)-10,12-dihydro[b,f]azepine difumarate was prepared, and examined for its GPR4 antagonistic effect and TNF- α production inhibitory effect in vitro.
 IT 927822-00-2P 927822-02-4P 927822-04-6P
 927822-05-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of preventives and/or remedies for X-ray induced lung injury containing GPR4 signaling inhibitors)

RN 927822-00-2 CAPLUS
 CN Methanone, [4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]cyclohexyl](4-methyl-1-piperazinyl)-(CA INDEX NAME)




RN 927822-02-4 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-, ethyl ester (CA INDEX NAME)

L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 927822-04-6 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]- (CA INDEX NAME)



RN 927822-05-7 CAPLUS
 CN Methanone, [4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]cyclohexyl](4-methyl-1-piperazinyl)-, ethanedioate (1:7) (CA INDEX NAME)

CM 1

CRN 927822-00-2
 CMF C29 H40 N6 O



CM 2


CRN 144-62-7
 CMF C2 H2 O4



IT 864171-66-4P 864172-38-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preventives and/or remedies for X-ray induced lung injury contg. GPR4 signaling inhibitors)
 RN 864171-66-4 CAPLUS
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[trans-4-[(4-methyl-1-piperazinyl)methyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 864172-38-3 CAPLUS
 CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[cis-4-[(4-methyl-1-piperazinyl)methyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007227775 CAPLUS
 DOCUMENT NUMBER: 146:266782
 TITLE: Chemokine production inhibitor
 INVENTOR(S): Saki, Mayumi; Miura, Kazumi; Sasaki, Katsutoshi
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 83pp.
 CODEN: PIKXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
 WO 2007023880 A1 20070301 WO 2006-JP316560 20060824
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, GN, HR, HO, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
 KR, KE, LA, LC, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
 MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
 RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, GM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 RG, KZ, MD, RU, TJ, TM
 PRIORITY APPLN. INFO.: JP 2005-242994 A 20050824


OTHER SOURCE(S): MARPAT 146:266782
 GI



AB Disclosed are a chemokine production inhibitor comprising a substance capable of inhibiting the function involved in signal transduction of GPR4 as an active ingredient; a chemokine production inhibitor comprising a nitrogenated tricyclic compound represented by the formula I (R1 represents a (un)substituted heterocyclic group, -NR5aR5b where R5a and R5b independently represent H, a (un)substituted lower alkyl group or the like; R2 represents a H or the like; R3 and R4 independently represent a H or the like; n = 0 or 1; X represents -(CH2)2 or the like; and Y represents the formula II where Z represents CH or N; R8a and R8b independently represent H, a (un)substituted lower alkyl group or the like; and R9 represents H or the like), or a quaternary ammonium salt or pharmaco. acceptable salt thereof as an active ingredient; and others. The chemokine production inhibitor includes antisense oligonucleotide and


L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
 antibody which binds specified proteins. For example, a compd.
 2-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-ylmethyl)-8-(4-
 methylpiperazin-1-ylmethyl)-10,11-dihydro[b,f]azepine difumarate was
 prep'd., and exand. for its GPR4 antagonistic effect and IL-8 prodn.
 inhibitory effect in vitro.
 IT 864171-83-5P 864171-86-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (chemokine production inhibitor comprising substances capable of
 inhibiting
 GPR4 signal transduction)
 RN 864171-83-5 CAPLUS
 CN Methanone, (4-methyl-1-piperazinyl) [trans-4-[4-[(2,5,7-trimethyl-3H-
 imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]- (CA INDEX
 NAME)

Relative stereochemistry.



RN 864171-86-8 CAPLUS
 CN Cyclohexanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-4-[(4-[(2,5,7-
 trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-, trans-
 (CA
 INDEX NAME)

Relative stereochemistry.



IT 864172-71-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (chemokine production inhibitor comprising substances capable of
 inhibiting

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:979653 CAPLUS
 DOCUMENT NUMBER: 143:286426
 TITLE: Preparation of imidazo[4,5-b]pyridine derivatives as
 GPR4 receptor antagonists for treatment of
 neutrophilic inflammation
 INVENTOR(S): Iida, Kyoichiro; Otsubo, Nobumasa; Kuboyama, Takeshi;
 Arai, Hitoshi; Natanabe, Akihiko; Saki, Mayumi;
 Hiura,
 Naeke; Manabe, Haruhiko; Takada, Hidenori; Saito, Jun
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 178 pp.
 CODEN: PIXXD2


DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082904	A1	20050909	WO 2005-JP3656	20050225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
R: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2557276	A1	20050909	CA 2005-2557276	20050225
EP 1724271	A1	20061122	EP 2005-719958	20050225
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20070213361	A1	20070913	US 2006-590845	20060828
PRIORITY APPLN. INFO.:			JP 2004-50934	A 20040226
			JP 2004-307948	A 20041022
			WO 2005-JP3656	W 20050225

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 143:286426
 GI


L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
 GPR4 signal transduction)
 RN 864171-71-4 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[(4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.




IT 864172-28-1P
 RL: SFN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (chemokine production inhibitor comprising substances capable of
 inhibiting
 GPR4 signal transduction)
 RN 864172-28-1 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[(4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-, ethyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




AB The title compds. I [wherein R1 = H, halo, CN, etc.; A1-A2-A3-A4 = (un)substituted CH=CH-CH=CH, N=CH-CH=CH, CH=N-CH=CH, CH=CH-N=CH, CH=CH-CH=N, N=CH-N=CH, CH=N-CH=N, or N=CH-CH=N; Q = (un)substituted phenylene, naphthylene, heteroarylene, etc.]; I = CHO, (un)substituted alkyl, cycloalkyl, etc.] or pharmaceutically acceptable salts thereof are prepared as G protein-coupled receptor (GPR4) antagonists for the treatment of neutrophilic inflammation. For example, the compound II was prepared in a multi-step synthesis. II inhibited 97% of human GPR4 at the concentration of 1 μ M.

IT 864171-56-2P 864171-57-3P 864171-64-2P
 864171-65-3P 864171-67-5P 864171-68-6P
 864171-71-1P 864171-72-2P 864171-74-4P
 864171-76-6P 864171-79-9P 864171-81-3P
 864171-83-5P 864171-90-4P 864171-94-8P
 864172-07-6P 864172-27-0P 864172-28-1P
 864172-29-2P 864172-30-5P 864172-31-6P
 864172-35-0P 864172-37-2P 864172-39-4P
 864172-40-7P 864172-44-1P 864172-51-0P
 864172-53-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate); preparation of imidazo[4,5-b]pyridine derivs. as GPR4 receptor antagonists for treatment of neutrophilic inflammation)
 RN 864171-56-2 CAPLUS
 CN Benzoic acid, 4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-, ethyl ester (CA INDEX NAME)




RN 864171-57-3 CAPLUS
 CN Methanone, [4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]phenyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 864171-64-2 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-, ethyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-65-3 CAPLUS
CN Methanone,
[trans-4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]cyclohexyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-67-5 CAPLUS
CN Methanone,
[trans-4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]cyclohexyl]-4-morpholinyl- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-74-4 CAPLUS
CN Methanone,
[trans-4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]cyclohexyl][4-(hydroxymethyl)-1-piperidinyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-76-6 CAPLUS
CN Cyclohexanecarboxamide, 4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-N-[2-(1-pyrrolidinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-79-9 CAPLUS
CN Cyclohexanecarboxamide, 4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-N-(2-(4-morpholinyl)ethyl)-, trans- (CA INDEX NAME)




RN 864171-68-6 CAPLUS
CN Methanone,
[trans-4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]cyclohexyl]-1-pyrrolidinyl- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-71-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(trans-4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]cyclohexyl)carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Relative stereochemistry.




RN 864171-72-2 CAPLUS
CN Methanone,
[trans-4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]cyclohexyl]-1-piperazinyl- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-81-3 CAPLUS
CN Methanone,
[trans-4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]cyclohexyl][4-(4-morpholinyl)-1-piperidinyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-83-5 CAPLUS
CN Methanone, (4-methyl-1-piperazinyl)[trans-4-[(4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
 CN Cyclohexanecarboxamide,
 4-[(4-(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]amino]-N-[2-(4-morpholinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-94-8 CAPLUS
 CN Cyclohexanecarboxamide, 4-[(4-[(2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-N-[2-(4-morpholinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-07-6 CAPLUS
 CN 1,4-Dioxaspiro[4.5]decan-8-amine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]- (CA INDEX NAME)

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 864172-27-0 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[(4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-, ethyl ester, cis- (CA INDEX NAME)

Relative stereochemistry.



RN 864172-28-1 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[(4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-, ethyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-29-2 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[(4-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-, ethyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 864172-30-5 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[(4-[(2-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-, ethyl ester, trans- (CA INDEX NAME)


Relative stereochemistry.



RN 864172-31-6 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[(4-[(2-(2-furanyl)-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-, ethyl ester, trans- (CA INDEX NAME)


Relative stereochemistry.

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 864172-35-0 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[(4-[(5-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-, ethyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-37-2 CAPLUS
 CN Methanone, [cis-4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]cyclohexyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-39-4 CAPLUS
CN Methanone, [cis-4-[(4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-40-7 CAPLUS
CN Methanone, [cis-4-[(4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]amino]cyclohexyl]-1-pyrrolidinyl- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-44-1 CAPLUS
CN Methanone, (4-methyl-1-piperazinyl)[cis-4-[(4-(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-51-0 CAPLUS
CN Methanone, 4-morpholinyl[cis-4-[(4-(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]amino]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 864171-55-1 CAPLUS
CN Benzenamine, 3-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-phenyl- (CA INDEX NAME)




RN 864171-58-4 CAPLUS
CN Benzenemethanol, 4-[(4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]amino- (CA INDEX NAME)



RN 864171-60-8 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[4-(4-methyl-1-piperazinyl)methyl]phenyl]-, (2E)-2-butenedioate (1:2) (CA INDEX NAME)

CM 1


CRN 864171-59-5
CMF C29 H36 N6



CM 2


RN 864172-53-2 CAPLUS
CN Methanone, [4-(hydroxymethyl)-1-piperidinyl][cis-4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




IT 864171-54-0P 864171-55-1P 864171-58-4P
864171-60-8P 864171-62-0P 864171-66-4P
864171-69-7P 864171-70-0P 864171-73-3P
864171-75-5P 864171-78-8P 864171-80-2P
864171-82-4P 864171-84-6P 864171-85-7P
864171-86-9P 864171-89-3P 864171-88-0P
864171-89-1P 864171-91-5P 864171-92-6P
864171-93-7P 864171-95-9P 864171-96-0P
864171-97-1P 864172-10-1P 864172-21-4P
864172-22-5P 864172-32-7P 864172-33-8P
864172-34-9P 864172-36-1P 864172-38-3P
864172-42-9P 864172-43-0P 864172-45-2P
864172-46-3P 864172-48-5P 864172-49-6P
864172-50-9P 864172-52-1P 864172-54-3P
RL: PAC (Pharmacological activity); SPT (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of imidazo[4,5-b]pyridine derivs. as GPR4 receptor antagonists for treatment of neutrophilic inflammation)
RN 864171-54-0 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-phenyl- (CA INDEX NAME)

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CRN 110-17-8 CMF C4 H4 O4
Double bond geometry as shown.




RN 864171-62-0 CAPLUS
CN Benzenamine, N-cyclohexyl-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)




RN 864171-66-4 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[trans-4-(4-methyl-1-piperazinyl)methyl]cyclohexyl- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-69-7 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[trans-4-(4-morpholinylmethyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-70-0 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[trans-4-(1-pyrrolidinylmethyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-73-3 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[trans-4-(1-piperazinylmethyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 864171-75-5 CAPLUS
CN 4-Piperidinemethanol, 1-[[trans-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 864171-78-8 CAPLUS
CN 1-Pyrrolidineethanamine, N-[[trans-4-[[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]-ethanedioate (1?) (CA INDEX NAME)

CM 1


CRN 864171-77-7
CMF C30 H44 N6

Relative stereochemistry.




RN 864171-84-6 CAPLUS
CN Benzenamine, N-[trans-4-[(4-methyl-1-piperazinyl)methyl]cyclohexyl]-4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-85-7 CAPLUS
CN Cyclohexanecarboxamide, N-[2-(4-morpholinyl)ethyl]-4-[(4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.



RN 864171-86-8 CAPLUS
CN Cyclohexanecarboxamide, N-[2-(1-pyrrolidinyl)ethyl]-4-[(4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 864171-80-2 CAPLUS
CN 4-Morpholineethanamine, N-[[trans-4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 864171-82-4 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[trans-4-[(4-(4-morpholinyl)-1-piperidinyl)methyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 864171-87-9 CAPLUS


CN 4-Morpholineethanamine, N-[[trans-4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-88-0 CAPLUS
CN Methanone,
[4-(4-morpholinyl)-1-piperidinyl][trans-4-[(4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-89-1 CAPLUS
CN Benzenamine, N-[trans-4-[(4-(4-morpholinyl)-1-piperidinyl)methyl]cyclohexyl]-4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-91-5 CAPLUS
 CN Methanone, [trans-4-[4-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-92-6 CAPLUS
 CN Cyclohexanecarboxamide, 4-[(4-(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]amino-N-[2-(1-pyrrolidinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-93-7 CAPLUS
 CN 4-Morpholineethanamine, N-[(trans-4-[(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]cyclohexylmethyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-95-9 CAPLUS
 CN Methanone, [trans-4-[4-[(2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-96-0 CAPLUS
 CN Cyclohexanecarboxamide, 4-[(4-(2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]amino-N-[2-(1-pyrrolidinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864171-97-1 CAPLUS
 CN 4-Morpholineethanamine, N-[(trans-4-[(4-(2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]amino)cyclohexylmethyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-10-1 CAPLUS
 CN Cyclohexanone, 4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]- (CA INDEX NAME)



RN 864172-21-4 CAPLUS
 CN Cyclohexanecarboxamide, 4-[(4-[(2-furanyl)-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino-N-[2-(4-morpholinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 864172-22-5 CAPLUS
 CN Methanone, [trans-4-[(4-[(2-furanyl)-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 864172-32-7 CAPLUS
CN Methanone, [trans-4-[(4-[(5-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]cyclohexyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-33-8 CAPLUS
CN Cyclohexanecarboxamide, 4-[(4-[(5-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-N-[2-(4-morpholinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.



L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
RN 864172-38-3 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[cis-4-(4-methyl-1-piperazinyl)methyl]cyclohexyl- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-42-9 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[cis-4-(4-morpholinylmethyl)cyclohexyl]-, ethanedioate (2:1) (CA INDEX NAME)

CM 1

CRN 864172-41-8
CMF C28 H39 N5 O

Relative stereochemistry.




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 864172-43-0 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[cis-4-(1-pyrrolidinylmethyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.





RN 864172-34-9 CAPLUS
CN Cyclohexanecarboxamide, 4-[(4-[(5-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-N-[2-(1-pyrrolidinyl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-36-1 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[(4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-, ethyl ester, cis- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-45-2 CAPLUS
CN Benzenamine, N-[cis-4-[(4-methyl-1-piperazinyl)methyl]cyclohexyl]-4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 864172-46-3 CAPLUS
CN Cyclohexanecarboxamide, N-[2-(4-morpholinyl)ethyl]-4-[(4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]-, cis- (CA INDEX NAME)


Relative stereochemistry.



RN 864172-48-5 CAPLUS
CN 4-Morpholineethanamine, N-[cis-4-[(4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl)amino]cyclohexyl]methyl]-, ethanedioate (1:2) (CA INDEX NAME)

CM 1

Relative stereochemistry.




CM 2

CRN 144-62-7
 CMF C2 H2 O4




RN 864172-49-6 CAPLUS
 CN Methanone, [4-(4-morpholinyl)-1-piperidinyl][cis-4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-50-9 CAPLUS
 CN Benzenamine,
 N-[cis-4-[(4-morpholinyl)-1-piperidinyl]methyl]cyclohexyl]-
 4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-52-1 CAPLUS
 CN Benzenamine,
 N-[cis-4-(4-morpholinylmethyl)cyclohexyl]-4-[(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-54-3 CAPLUS
 CN 1-[[cis-4-[(4-(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)amino]cyclohexyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.




IT 864172-62-3P 864172-69-0P 864172-71-4P
 864172-73-6P 864172-74-7P 864172-75-8P
 864172-76-9P 864172-77-0P 864172-82-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of imidazo[4,5-b]pyridine derivs. as GPR4 receptor antagonists for treatment of neutrophilic inflammation)

RN 864172-62-3 CAPLUS
 CN Benzoic acid, 4-[(4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]amino]- (CA INDEX NAME)




RN 864172-69-0 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[(4-(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-71-4 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[(4-(2,5,7-trimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-73-6 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[(4-(2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-74-7 CAPLUS
 CN Cyclohexanecarboxylic acid,
 4-[(4-(2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]amino]-, trans- (CA INDEX NAME)




RN 864172-75-8 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[(4-(2-furanyl)-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-76-9 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[(4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-77-0 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[(4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 864172-82-7 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[{4-[{(5-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl}amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.



IT 864172-41-8P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazo[4,5-b]pyridine derivs. as GPR4 receptor antagonists
for treatment of neutrophilic inflammation)
RN 864172-41-8 CAPLUS
CN Benzenamine, 4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[cis-4-(4-morpholinylmethyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
N-tetrazolylmethyl deriv. II (V = Q6, R = Q5) (presumably angiotensin II receptor antagonist) in 3 steps.
IT 164520-40-5P 164520-41-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate for preparation of
N-phenyl-p-(heterocyclymethyl)aniline and
(heterocyclymethyl)dibenzazepine derivs. as angiotensin II receptor antagonists)
RN 164520-40-5 CAPLUS
CN Acetonitrile, 2-[{4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl}phenylamino]- (CA INDEX NAME)

RN 164520-41-6 CAPLUS
CN 1H-Tetrazole-5-methanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-N-phenyl-1-(triphenylmethyl)- (CA INDEX NAME)

IT 164520-43-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of N-phenyl-p-(heterocyclymethyl)aniline and
(heterocyclymethyl)dibenzazepine derivs. as angiotensin II receptor antagonists)
RN 164520-43-8 CAPLUS
CN 2H-Tetrazole-5-methanamine, N-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-N-phenyl- (CA INDEX NAME)

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1995:657621 CAPLUS
DOCUMENT NUMBER: 123:55878
ORIGINAL REFERENCE NO.: 123:10063a,10066a
TITLE: Preparation of N-phenyl-4-(heterocyclymethyl)aniline and (heterocyclymethyl)dibenz[b,f]azepine

derivatives
INVENTOR(S): Mori, Shinichiro; Nakajo, Iwao; Ogasa, Takehiro; Kasai, Masaji; Tomioka, Shinji; Ooshima, Etsuo; Kanai,

Fumihibe; Kumazawa, Toshiaki
Kyowa Hakko Kogyo Kk, Japan
Jpn. Kokai Tokkyo Koho, 17 pp.

CODEN: JKXKAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07061983	A	19950307	JP 1993-210419	19930825
			JP 1993-210419	19930825

OTHER SOURCE(S): CASREACT 123:55878; MARPAT 123:55878
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The title compds. [I; V = H, (CH₂)_mP (wherein m = 1-3; P = cyano, CO₂H, tetrazolyl, cyanophenyl, carboxyphenyl, tetrazolylphenyl); X₁ = X₂ = H or X₁X₂ = CH₂, O, S, CH₂O, OCH₂, CH₂S, SCH₂, CH₂CH; R = Q, Q₁, N(COR)₂CHR₉, Q₂; R₄, R₅ = H, halo, alkyl, cycloalkyl, haloalkyl, OH, CH₂OH, alkoxy, alkylamino, CO₂H, alkoxy carbonyl, ZL-22-23-24 = NiCHCH₂CH, CH₂CH₂CH, (CH₂)₄, R₇, R₈ = H, alkyl, cycloalkyl; R₉ = CO₂H, alkoxy carbonyl, CONH₂, CH₂OH, R₁₀, R₁₁ = H, alkyl; Z = N, CH] are prepared

by reaction of quaternary ammonium salts I [R = N+R₁R₂R₃, Q₃; R₁ = alkyl, allyl, CH₂Ph; R₂, R₃ = alkyl, cycloalkyl; Y = halo, alkoxy sulfonyloxy, aryloxysulfonyloxy, alkylsulfonyloxy, arylsulfonyloxy; W = H, alkyl, Ph;

Z = CH₂, S, O, (un)substituted NH; n = 1-3] with (heterocyclic) amines H-Q, H-Q₁, HN(COR)₂HR₉, and H-Q₂. They are useful as antagonists of angiotensin II receptor for the treatment of hypertension, ischemic heart failure, kidney failure, and glaucoma (no data) or intermediates thereof. Thus, 173 g dibenz[b,f]azepine derivative (II; R = piperidino) was dissolved

in EtOAc followed by adding 46.5 mL MeI and the resulting mixture was stirred at 40° for 8 h to give a quaternary ammonium salt II (V = H, R = Q₄). 2-Ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine (36.55 g) was dissolved in DMF and after adding 5.62 g LiOH, stirred at room temperature for 15 min. To the resulting mixture were added the latter salt II (V = H,

R = Q₄) and DMF and the resulting mixture was stirred at 40° for 8 h to give 45.9% of a title compound II (V = H, R = Q₅) which was converted into the



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	23.74	227.30
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.40	-3.40

STN INTERNATIONAL LOGOFF AT 10:44:24 ON 08 JUL 2010